Pierre-Alain Ruffini

Based in Basel, Switzerland, Lonza has built a global network of manufacturing facilities that produce some of the world's most important medicines — from monoclonal antibodies and biologics to mRNA vaccines and cell & gene therapies. Lonza's value proposition is that developing and manufacturing biological drugs requires enormous capital investment and specialized expertise that many pharmaceutical companies prefer to outsource. Building a biologics manufacturing facility costs hundreds of millions of dollars and takes years, making Lonza's existing capacity a critical and scarce resource. The company's customer relationships are exceptionally sticky — once a drug is manufactured at a Lonza facility, switching to another manufacturer requires extensive regulatory revalidation. Lonza gained particular visibility during the COVID-19 pandemic as a key manufacturer of Moderna's mRNA vaccine. The company has since been investing heavily in expanding capacity for cell & gene therapies (one of the fastest-growing areas of pharmaceutical development) and next-generation biologics. Key stock drivers include biologics manufacturing demand, new capacity utilization ramp, cell & gene therapy market growth, customer contract wins (which are often multi-year), pricing power in a capacity-constrained market, and the overall health of pharmaceutical R&D pipelines.